Yenerel, M. N. Et Al. 2023. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. ADVANCES IN THERAPY , vol.40, no.1 , 211-232.

Yenerel, M. N., de Fontbrune, F. S., Piatek, C., ŞAHİN, F., Fuereder, W., Ortiz, S., ... Ogawa, M.(2023). Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. ADVANCES IN THERAPY , vol.40, no.1, 211-232.

Yenerel, Mustafa Et Al. "Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up," ADVANCES IN THERAPY , vol.40, no.1, 211-232, 2023

Yenerel, Mustafa N. Et Al. "Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up." ADVANCES IN THERAPY , vol.40, no.1, pp.211-232, 2023

Yenerel, M. N. Et Al. (2023) . "Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up." ADVANCES IN THERAPY , vol.40, no.1, pp.211-232.

@article{article, author={Mustafa Nuri YENEREL Et Al. }, title={Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up}, journal={ADVANCES IN THERAPY}, year=2023, pages={211-232} }